5 FDA Decisions to Watch in the Second Half of 2024

cafead

Administrator
Staff member
  • cafead   Jun 24, 2024 at 11:32: AM
via There has been no shortage of landmark approvals from the FDA this year. From the first tumor-infiltrating lymphocytes therapy to the first gene therapy for a rare pediatric disease to the first targeted therapy for MASH, 2024 has already seen its fair share.

article source